Luckily, the ERS of 2022 was held live in Barcelona, Spain, with lots of ‘physical’ attendees. And many other interested colleagues could follow many sessions online. Again, numerous speakers were able to present the most recent updates in important areas of pulmonary diseases. Some of these studies and findings are highlighted below.
An awake prone position did not result in improved clinical outcomes compared with usual care in patients with acute hypoxemic respiratory failure from COVID-19. Although the intervention appeared to be safe, maintaining a prone position for many hours is challenging for patients. The full paper has been published in JAMA.
Complement activation (C5a) has been shown to play an important role in severe COVID-19 and vilobelimab is a first-in-class anti-C5a monoclonal antibody. C5a levels are high in patients with severe COVID-19 and are related to disease severity. Vilobelimab may reduce mortality in patients with severe COVID-19 pneumonia, the phase 3 PANAMO trial showed.
A post-COVID syndrome (PCS) scoring tool was developed, including the entire clinical spectrum of PCS in 12 binary questions. The tool was validated and could potentially be used for the diagnosis and stratification of patients with PCS. Also, the scoring tool could serve as a possible endpoint for clinical studies.
The addition of icenticaftor on top of triple inhalation therapy for 24 weeks resulted in a clear dose-response on 5 endpoints in patients with COPD and chronic bronchitis. The 300 mg, twice-daily dose of the drug showed an encouraging benefit-risk profile and will be investigated in further trials.
A point-of-care, eosinophil-guided prescription of prednisolone was non-inferior to standard-of-care prescription of prednisolone in the treatment of COPD exacerbations, the multicentre, randomised STARR2 trial showed.
Tezepelumab reduced mucus plugging in patients with moderate-to-severe asthma. Moreover, reductions in mucus scores correlated with improvements in lung function. Tezepelumab is the first biologic agent to demonstrate these results in a randomised-controlled trial.
This report outlines the most significant advancements discussed at the ERS conference. So, we hope that you will enjoy reading this Conference Report!
Stay healthy and kind regards,
Prof. em. Richard Dekhuijzen
Prof. P.N. Richard Dekhuijzen is Professor of Pulmonology at the Radboud University Medical Center in Nijmegen, the Netherlands. His specific area of clinical and research interest includes asthma, COPD, and inhalation technology. He studied medicine at VU Amsterdam and completed his training in pulmonology at the Onze Lieve Vrouwe Gasthuis in Amsterdam and in the Academic Hospital Nijmegen. In 1989, he finished his PhD thesis on training of the respiratory muscles in COPD, followed by a PhD thesis on steroid induced myopathy of the diaphragm in 1994 at the Catholic University Leuven (Belgium). He is author/co-author of over 330 peer-reviewed papers and many textbook chapters on respiratory medicine. From 2008-2010, he was Head of the Cardiology Department at Radboudumc. Until 2016, he chaired the Department of Pulmonary Diseases, the Heart-Lung Centre Nijmegen, and the Medical Staff at Radboudumc. He is the scientific chair of the Aerosol Drug Management Improvement Team (ADMIT) and chair of the Dutch Inhalation Technology Working Group. Currently, he is chair of the Medical Ethical Committee of the Radboudumc.
Conflict of Interest Statement: In the last 3 years, Richard Dekhuijzen and/or his department received research grants, unrestricted educational grants, and/or fees for lectures and advisory board meetings from AstraZeneca, Boehringer-Ingelheim, Chiesi, GSK, Mundipharma, Novartis, Sandoz, Teva, and Zambon.
« Study fails to show non-inferiority of rituximab with ocrelizumab Next Article
Roflumilast foam led to high response rates in seborrheic dermatitis »
Table of Contents: ERS 2022
Letter from the Editor
ERS 2022 Highlights Podcast
COVID-19: What Is New?
Does vilobelimab reduce mortality in severe COVID-19?
Awake proning not positive in COVID-19
Favipiravir may help patients over 60 years with COVID-19 to recover
Brensocatib fails in severe COVID-19
Inhaled agent under investigation for COVID-19
Accurate voice-based COVID-19 diagnostic test in development
Novel scoring tool for post-COVID syndrome aids clinicians and researchers
COPD: Therapies and Innovations
Icenticaftor achieves results on top of triple inhalation therapy in COPD
STARR2: A new approach for treating COPD exacerbations
COPD medication not effective in symptomatic smokers with preserved spirometry
Do digital tools improve physical activity in COPD?
Hyperpolarised gas MRI ready for clinical use
All About Asthma
Tezepelumab in asthma: mucus plugging down, lung function up
Digital asthma intervention improves health and reduces costs
Digitally enhanced therapy lowers treatment burden and costs in severe asthma
Mepolizumab beneficial for patients with severe eosinophilic asthma
Progress in Paediatrics
Antibiotics cause increased risk of wheezing in severe RSV bronchiolitis
Inhaled corticosteroids useful in preterms with decreased lung function
Fish oil or vitamin D during pregnancy can prevent croup
Encouraging results of nintedanib in children with fibrosing ILD
Focus on Interventional Pulmonology
Head-to-head: lung volume reduction surgery vs endobronchial valves
Durable effect of endobronchial valves in severe emphysema
Cone beam CT-guided ENB improves detection of pulmonary nodules
Confirmatory mediastinoscopy not needed in resectable NSCLC
Sleep and Breathing Disorders
In the spotlight: Cancer trends in obstructive sleep apnoea
Impact of CPAP on cardiac endpoints in OSA
Sustained hypoxaemia predicts unprovoked VTE in OSA
CPAP therapy in the prevention of cardiovascular risk in patients with OSA
Other Remarkable Research
Excellent results for high-flow nasal cannula oxygen therapy in acute respiratory failure
Antifibrotic therapy may slow down FVC decline in RAILD
Intravenous N-acetylcysteine performs well in hospitalised patients
Men and women respond differently to diesel exhaust
New trends in cystic lung diseases
Awake proning not positive in COVID-19